<DOC>
	<DOCNO>NCT00532571</DOCNO>
	<brief_summary>To compare efficacy , safety tolerability Coenzyme Q 10 versus placebo patient atypical parkinsonian syndrome corticobasal degeneration ( CBD ) progressive supranuclear palsy ( PSP ) ) .</brief_summary>
	<brief_title>Effects Coenzyme Q10 PSP CBD</brief_title>
	<detailed_description />
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Patients fulfil diagnostic criterion PSP CBD ( ) diagnose within past 5 year Age &gt; 40 Subjects receive anticholinergic , amantadine , dopamine agonist , carbidopa/levodopa , eldepryl , comtan must stable dose least 30 day prior baseline visit . Patients agreeable participate study . Prior concurrent therapy anticholinergic , amantadine , dopamine agonist , carbidopa/levodopa comtan within 30 day baseline visit . Parkinsons disease atypical parkinsonism ; Parkinsonism due drug . History pallidotomy , thalamotomy , deep brain stimulation fetal tissue transplant . Previous use coenzyme Q10 within 60 day baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>CoQ10</keyword>
	<keyword>PSP</keyword>
	<keyword>CBD</keyword>
</DOC>